We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
More than two years ago, when Allergan inked a $2.1 billion pact for Kythera, Bernstein analyst Ronny Gal wrote to clients that Allergan “obviously” has “much higher expectations than we do” for chin-fat drug Kybella.